Author

Eitan Kerem

Hadassah Medical CenterORCID 0000-0002-4635-386XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2

Frequent Co-Authors

Batsheva KeremiD· 2 shared Anita GoleciD· 1 shared Aryeh M. Weiss· 1 shared Aurélie HattoniD· 1 shared Chen LeibsoniD· 1 shared Deborah Duran· 1 shared Efrat Ozeri-GalaiiD· 1 shared Eric J. SorscheriD· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Batsheva KeremORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CFTR structures bound to ETI components predict rare mutation response to modulator combinations

Noemie Stanleigh, Michal Gur, Michal Shteinberg, Aryeh M. Weiss, Naama Sebbag-Sznajder, Deborah Duran, Myriam Grunewald, Liron Birimberg‐Schwartz, Ronen Bar‐Yoseph, Jeffrey Matthijn Beekman, Eitan Kerem, Michael A. Wilschanski, Batsheva Kerem

The paper predicts and validates responses to CFTR modulator combinations in patients with rare mutations using structural data and functional assays.

medRxiv · Oct 12, 2024 · PreprintGenetic & Genomic Medicine

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation

Yifat S. Oren, Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao, Jeong Shin Hong, Efrat Ozeri-Galai, Aurélie Hatton, Chen Leibson, Liran Carmel, Joel M. Reiter, Eric J. Sorscher, Steve Donald Wilton, Eitan Kerem, , Batsheva Kerem

This study develops an antisense oligonucleotide (ASO) therapy for CF patients with the 3849+10kb C-to-T splicing mutation, showing restoration of CFTR function in patient-derived cells.

Journal of Cystic Fibrosis · Jul 2, 2021Peer-reviewedGenetics